This study will combine cabozantinib with pemetrexed to treat patients with non-small cell lung cancer, urothelial cancer and advanced malignant mesothelioma. This study will test the safety of both drugs used together and see what effect (good or bad) it has no participants and their cancer.
| Overal Status | Start Date | Phase | Study Type |
|---|---|---|---|
| Recruiting | January 23, 2020 | Phase 1 | Interventional |
Primary Outcome 1 - Measure: Assess the maximum tolerated dose (MTD) of cabozantinib in combination with pemetrexed
Primary Outcome 1 - Time Frame: 4 weeks or 28 days assessment.
Criteria:
Inclusion Criteria:
- Locally advanced NSCLC, urothelial cancer or malignant mesothelioma.
- 18 years or older.
- At least one prior chemotherapy before entering in this trial.
- Not pregnant or breastfeeding.
Exclusion Criteria:
- Prior treatment with cabozantinib.
- Currently receiving cancer treatment (last dose 2 weeks prior to enrollment in study).
- History of bleeding disorder/bleeding history within 12 weeks before first study
treatment dose.
Show More
Gender: All
Minimum Age: 18 Years
Maximum Age: N/A
Healthy Volunteers: No
Name: Nagla A Karim, MD, PhD
Role: Principal Investigator
Affiliation: Augusta University Georgia Cancer Center
Name: Kelly Jenkins, MSN, RN
Phone: 706-721-1206
Email: kejenkins@augusta.edu
| Facility | Status | Contact |
|---|---|---|
| Augusta University Georgia Cancer Center Augusta, Georgia 30912 United States |
Recruiting |
